KalVista - KalVista Pharmaceuticals
KalVista is advancing science to empower everyday lives with innovative oral medicines. KalVista’s mission begins with hereditary angioedema, HAE. Patients & Caregivers
About Us - KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system.
Pipeline - KalVista Pharmaceuticals
KalVista is building a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development as potential best-in-class treatments for a range of diseases, beginning with hereditary angioedema (HAE).
KalVista Pharmaceuticals, Inc. (KALV) Stock Price, News, Quote ...
Find the latest KalVista Pharmaceuticals, Inc. (KALV) stock quote, history, news and other vital information to help you with your stock trading and investing.
KalVista Pharmaceuticals, Inc. (KALV) - Stock Analysis
2 days ago · Get a real-time KalVista Pharmaceuticals, Inc. (KALV) stock price quote with breaking news, financials, statistics, charts and more.
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic …
Nov 4, 2024 · KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet need.
KalVista Announces Orphan Drug Designation and NDA …
4 days ago · CAMBRIDGE, Mass. & SALISBURY, England, January 21, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted ...
KalVista Announces FDA Acceptance of New Drug Application for ...
Sep 3, 2024 · KalVista announced positive phase 3 data from the KONFIDENT trial for its oral, on-demand therapy, sebetralstat for HAE in February 2024. The Company’s NDA for sebetralstat has been accepted by the FDA with a PDUFA goal date of June 17, 2025 .
| KalVista Pharmaceuticals
The Investor Relations website contains information about KalVista Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
KalVista Announces FDA Acceptance of New Drug Application for ...
Sep 3, 2024 · CAMBRIDGE, Mass. & SALISBURY, England, September 03, 2024 -- (BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S. Food and Drug Administration (FDA) has...